KPIs & Operating Metrics(New)
Additions To Property And EquipmentAdjusted Income Before TaxAdjusted Income Before Tax By SegmentAssets By SegmentBreakdown Of AssetsCardiovascular/Metabolism/Other RevenueCardiovascular/Metabolism/Other Revenue AnnualConsumer RevenueContractual BoligationsCost Of Products SoldDisaggregated Revenue Mix %Disaggregated RevenuesEarnings Before Taxes On IncomeEbt By SegmentEbt By Segment AnnualEbt Margin By Segment Annual %Employee StatisticsFacilites By RegionGross Margin %Gross ProfitImmunology RevenueImmunology Revenue AnnualInfectious Diseases RevenueInfectious Diseases Revenue AnnualInnovative Medicine Revenue Breakdown AnnualInternational Sales By SegmentInterventional Solutions Revenue AnnualInventoriesLong Lived Assets By RegionMedical Devices RevenueMedical Devices Revenue AnnualMedtech Revenue Breakdown AnnualNeurosciences RevenueNeurosciences Revenue AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Oncology RevenueOncology Revenue AnnualOpex As A % Of RevenueOPEX SegregationOrthopaedics Revenue AnnualPharmaceutical Revenue BreakdownProperty And Equipment SegregationPulmonary Hypertension RevenuePulmonary Hypertension Revenue AnnualRevenue By ProductRevenue By Product %Revenue By RegionRevenue By Region %Revenue By Region (Annual)Revenue By Region (Annual) %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Square Footage By RegionSurgery Revenue AnnualUs Sales By SegmentVision Revenue Annual
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Johnson & Johnson (JNJ) Gross Profit (2016 - 2025)

Johnson & Johnson's Gross Profit history spans 18 years, with the latest figure at $16.0 billion for Q1 2026.

  • On a quarterly basis, Gross Profit rose 9.77% to $16.0 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $65.4 billion, a 7.12% increase, with the full-year FY2025 number at $63.9 billion, up 4.22% from a year prior.
  • Gross Profit hit $16.0 billion in Q1 2026 for Johnson & Johnson, down from $16.6 billion in the prior quarter.
  • Over the last five years, Gross Profit for JNJ hit a ceiling of $16.7 billion in Q3 2025 and a floor of $13.8 billion in Q2 2022.
  • Historically, Gross Profit has averaged $15.0 billion across 5 years, with a median of $14.9 billion in 2024.
  • Biggest five-year swings in Gross Profit: fell 14.07% in 2022 and later grew 9.77% in 2026.
  • Tracing JNJ's Gross Profit over 5 years: stood at $13.8 billion in 2022, then rose by 5.59% to $14.6 billion in 2023, then rose by 5.45% to $15.4 billion in 2024, then rose by 7.82% to $16.6 billion in 2025, then fell by 3.86% to $16.0 billion in 2026.
  • Business Quant data shows Gross Profit for JNJ at $16.0 billion in Q1 2026, $16.6 billion in Q4 2025, and $16.7 billion in Q3 2025.